These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34780933)

  • 1. Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs.
    Yu L; Hua Z; Luo X; Zhao T; Liu Y
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188655. PubMed ID: 34780933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights into the pleiotropic effects of human serum albumin in health and disease.
    Ha CE; Bhagavan NV
    Biochim Biophys Acta; 2013 Dec; 1830(12):5486-93. PubMed ID: 23602811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Albumin, Lipid and Drug Binding.
    Nishi K; Yamasaki K; Otagiri M
    Subcell Biochem; 2020; 94():383-397. PubMed ID: 32189308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human plasma lipocalins and serum albumin: Plasma alternative carriers?
    di Masi A; Trezza V; Leboffe L; Ascenzi P
    J Control Release; 2016 Apr; 228():191-205. PubMed ID: 26951925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the interaction between human serum albumin and anti-bacterial/ anti-cancer compounds.
    Rehman MT; Khan AU
    Curr Pharm Des; 2015; 21(14):1785-99. PubMed ID: 25738491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulation of zinc speciation by fatty acids.
    Barnett JP; Blindauer CA; Kassaar O; Khazaipoul S; Martin EM; Sadler PJ; Stewart AJ
    Biochim Biophys Acta; 2013 Dec; 1830(12):5456-64. PubMed ID: 23726993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR identification of endogenous metabolites interacting with fatted and non-fatted human serum albumin in blood plasma: Fatty acids influence the HSA-metabolite interaction.
    Jupin M; Michiels PJ; Girard FC; Spraul M; Wijmenga SS
    J Magn Reson; 2013 Mar; 228():81-94. PubMed ID: 23357430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing albumin as a carrier for cancer therapies.
    Hoogenboezem EN; Duvall CL
    Adv Drug Deliv Rev; 2018 May; 130():73-89. PubMed ID: 30012492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand binding strategies of human serum albumin: how can the cargo be utilized?
    Varshney A; Sen P; Ahmad E; Rehan M; Subbarao N; Khan RH
    Chirality; 2010 Jan; 22(1):77-87. PubMed ID: 19319989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR metabolomics profiling of blood plasma mimics shows that medium- and long-chain fatty acids differently release metabolites from human serum albumin.
    Jupin M; Michiels PJ; Girard FC; Spraul M; Wijmenga SS
    J Magn Reson; 2014 Feb; 239():34-43. PubMed ID: 24374750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance.
    Bertucci C; Domenici E
    Curr Med Chem; 2002 Aug; 9(15):1463-81. PubMed ID: 12173977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin.
    Bhattacharya AA; Grüne T; Curry S
    J Mol Biol; 2000 Nov; 303(5):721-32. PubMed ID: 11061971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsically Disordered Regions in Serum Albumin: What Are They For?
    Litus EA; Permyakov SE; Uversky VN; Permyakov EA
    Cell Biochem Biophys; 2018 Jun; 76(1-2):39-57. PubMed ID: 28281231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Synthetic Anticancer Approach by Resourcing Mouse Blood Albumin as a Biocompatible Artificial Metalloenzyme.
    Imai K; Muguruma K; Nakamura A; Kusakari Y; Chang TC; Pradipta AR; Tanaka K
    Angew Chem Int Ed Engl; 2024 Oct; 63(43):e202411225. PubMed ID: 38989662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.
    Kurtzhals P; Havelund S; Jonassen I; Kiehr B; Larsen UD; Ribel U; Markussen J
    Biochem J; 1995 Dec; 312 ( Pt 3)(Pt 3):725-31. PubMed ID: 8554512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Updates on Interaction Studies and Drug Delivery of Antimalarials with Serum Albumin Proteins.
    Azeem K; Irfan I; Rashid Q; Singh S; Patel R; Abid M
    Curr Med Chem; 2024; 31(25):3925-3953. PubMed ID: 37218197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites.
    Curry S; Mandelkow H; Brick P; Franks N
    Nat Struct Biol; 1998 Sep; 5(9):827-35. PubMed ID: 9731778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin-drug interaction and its clinical implication.
    Yamasaki K; Chuang VT; Maruyama T; Otagiri M
    Biochim Biophys Acta; 2013 Dec; 1830(12):5435-43. PubMed ID: 23665585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis.
    Simard JR; Zunszain PA; Hamilton JA; Curry S
    J Mol Biol; 2006 Aug; 361(2):336-51. PubMed ID: 16844140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis.
    Kragh-Hansen U; Watanabe H; Nakajou K; Iwao Y; Otagiri M
    J Mol Biol; 2006 Oct; 363(3):702-12. PubMed ID: 16979183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.